As China strives towards economic recovery, a senior executive of global pharmaceutical giant Pfizer has expressed confidence in the country's economy. Jean-Christophe Pointeau, the president of Pfizer China, shared his view with China.org.cn during the annual "two sessions" on Wednesday, expressing the company's belief in China's sustained economic development.

 Jean-Christophe Pointeau, president of Pfizer China. [Photo provided to China.org.cn]

"From the 20th National Congress of the CPC to the Central Economic Work Conference, and to the government report of the 'two sessions,' the thing we heard the most is to boost confidence in economic development,” Pointeau noted.

"From our perspective, Pfizer is full of confidence in the sustained development of China's economy. We have witnessed and felt the Chinese government's determination to further deepen high-quality opening-up and to attract foreign investment and the vitality of the rebounding Chinese market," said Pointeau.

Pointeau emphasized that China's economy has strong resilience and enormous potential, which has been reinforced by the continuously optimized business environment and the launch of favorable policies. This has encouraged foreign multinational corporations to invest in the country, consolidating the confidence of many foreign pharmaceutical companies, including Pfizer, to put down roots in China and integrate with the nation's economic development.

"The Chinese market is providing more opportunities and space for companies all over the world. Pfizer has always been committed to delivering breakthroughs that change patients' lives, and the company has made notable contributions in improving access to innovative drugs in recent years. Pfizer has continued to accelerate innovation and provide Chinese patients with more of the world's leading innovative products and medical solutions, actively addressing their unmet clinical needs," he said.

Over the past 30 years since entering China, Pfizer has introduced over 60 innovative drugs to the country, benefiting millions of Chinese patients. Currently, there are 110 discovery projects in Pfizer's global R&D pipeline, and Pfizer China is actively participating in around 80% of the pivotal trials in the U.S. and EU, which means that Chinese patients will have faster access to the company's global innovative breakthrough therapies.

Pointeau emphasized Pfizer's commitment to the Chinese market, saying that the company will collaborate with all stakeholders to establish a resilient and flexible healthcare system, and take concrete actions to help build a healthy China.